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ABSTRACT
Introduction: Lower limb amputations have
detrimental influences on the quality of life, function
and body image of the affected patients. Following
amputation, prolonged rehabilitation is required for
patients to be fitted with traditional socket prostheses,
and many patients experience symptomatic socket–
residuum interface problems which lead to reduced
prosthetic use and quality of life. Osseointegration has
recently emerged as a novel approach for the
reconstruction of amputated limbs, which overcomes
many of the socket-related problems by directly
attaching the prosthesis to the skeletal residuum. To
date, the vast majority of osseointegration procedures
worldwide have been performed in 2 stages, which
require at least 4 months and up to 18 months for the
completion of reconstruction and rehabilitation from
the time of the initial surgery. The current prospective
cohort study evaluates the safety and efficacy of a
single-stage osseointegration procedure performed
under the Osseointegration Group of Australia
Accelerated Protocol-2 (OGAAP-2), which dramatically
reduces the time of recovery to ∼3–6 weeks.
Methods and analysis: The inclusion criteria for
osseointegrated reconstruction under the OGAAP-2
procedure are age over 18 years, unilateral transfemoral
amputation and experiencing problems or difficulties in
using socket prostheses. All patients receive
osseointegrated implants which are press-fitted into
the residual bone. Functional and quality-of-life
outcome measures are recorded preoperatively and at
defined postoperative follow-up intervals up to 2 years.
Postoperative adverse events are also recorded. The
preoperative and postoperative values are compared for
each outcome measure, and the benefits and harms of
the single-stage OGAAP-2 procedure will be compared
with the results obtained using a previously employed
2-stage procedure.
Ethics and dissemination: This study has received
ethics approval from the University of Notre Dame,
Sydney, Australia (014153S). The study outcomes will

Strengths and limitations of this study
▪ This study is the first study to describe, as well
as report on the safety and efficacy of, a singlestage procedure for the osseointegrated reconstruction of amputated limbs. This study may
therefore have significant influence on the standard of treatment for patients with lower limb
amputations
undergoing
osseointegration
surgery, and reverse the concept that a twostage procedure is required.
▪ This study has a relatively large sample size of
105 patients, which resembles one of the largest
patient cohorts among studies published to date
reporting on the outcomes of osseointegrated
reconstruction of amputated limbs.
▪ This study does not directly compare the outcomes of using osseointegrated prostheses to
the outcomes of using socket prostheses as the
traditional method of treating patients with lower
limb amputations.
▪ This study has a relatively short follow-up period
of 2 years, which does not allow the examination
of longer term outcomes and risk of adverse
events.
be disseminated by publications in peer-reviewed
academic journals and presentations at relevant clinical
and orthopaedic conferences.

INTRODUCTION
Lower limb amputations almost inevitably
result in major changes to the quality of life,
function and body image of the affected
patients,1–4 and are still associated with
considerable morbidity and mortality.5 For
patients with bilateral above-knee amputations,
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over 90% are eventually conﬁned to a wheelchair due to
the difﬁculty of mobilising with prostheses attached to
both lower limbs.6 The effect of amputation is greater in
younger and more active patients who must adapt to a
drastic reduction in mobility and the associated psychological consequences,4 which also often restricts their
ability to seek or continue employment.7 The
return-to-work rate for lower limb amputees is between
22% and 67%, with many having to change their occupation or work only part-time.8 Data pooled from study
populations in the UK, Europe, USA and parts of the
Asia-Paciﬁc indicate that the global incidence of all
forms of lower extremity amputation ranges from 5.8 to
31 per 105 in the total population.9
Following amputation, prolonged rehabilitation is
often required for patients to be ﬁtted with traditional
suspended socket prostheses. The ﬁtting generally
becomes more difﬁcult with amputation at higher levels,
and often results in characteristic symptoms of local
pain, skin ulceration and discomfort.2 10 11 In addition,
patients with a short stump, skin grafts, scarring or heterotopic bone formation may be entirely unable to use
socket prostheses, or choose not to use them due to the
problems associated with socket ﬁtting. A survey of 97
patients with transfemoral amputation in Sweden
reported a very high prevalence of problems related to
the use of socket prostheses, including: 72% with symptomatic heat and sweating of the stump, 62% with sores
or skin irritation from the socket, 61% with interference
to mobility and 51% with pain in the stump when standing or walking.2 In addition, these patients consistently
reported a signiﬁcantly diminished quality of life when
compared with able-bodied participants. The typical
socket prosthesis used for transfemoral amputations has
also been shown to hinder the range of motion of the
involved hip, which contributes further to difﬁculties in
ambulation.12 The problems associated with socket prostheses have remained largely unsolved, despite extensive
and continuing research into socket design and manufacturing.13 Consequently, at least one-third of all amputees still experience symptomatic socket–residuum
interface problems, leading to reduced prosthetic use
and markedly reduced quality of life.10 14
Osseointegration has emerged over the past two
decades as a dramatically different approach for the
reconstruction of limb loss due to amputation, which
can overcome many of the issues associated with traditional socket prostheses.15–17 The surgical procedure
involves direct attachment of the prosthesis to the skeletal residuum, in a process analogous to that used in
uncemented hip arthroplasty. A titanium intramedullary
implant is press-ﬁtted into the residual bone of the
amputated limb, which becomes rapidly incorporated
into the bone over the few months following surgery.
This implant is continuous with an abutment that penetrates the skin through a small permanent opening,
which is used for attachment of the prosthetic limb.
Osseointegrated prostheses can therefore completely
2

eliminate the problematic socket–residuum interface
due to the intimate structural and functional connection
between the intramedullary implant and host bone.
The Food and Drug Administration (FDA) recently
approved osseointegration surgery for amputees in the
USA, although for humanitarian indications only.18
Nevertheless, this technology has been employed
internationally for over 20 years and increasingly in
Europe, the UK and Australia over the past decade.
Osseointegration surgery for the reconstruction of
amputated limbs has mainly been performed using two
types of implants. Cannulated screw-ﬁxation implants,
originally developed in Sweden, achieve skeletal integration as a result of bone on-growth. Treatment requires
two operations, where an initial procedure is performed
to insert the intramedullary implant, and a second
procedure is performed 6–9 months later to create the
percutaneous skin opening for allowing abutment
attachment and prosthesis ﬁtting.19 Alternatively, press-ﬁt
macroporous surface structure implants allow skeletal
integration by bone penetration and ingrowth, which
also require a two-stage operation with a 6–8-week interval between stages.20 Several prospective case series
describing these two techniques have been published,
which reported on the major clinical beneﬁts of the
osseointegration approach, including improvements in
the patients’ quality of life,21 prosthetic use,21 22 body
image,22 hip range of motion,23 sitting comfort,12
donning and dofﬁng,21 osseoperception24 and walking
ability,16 25 as well as very acceptable levels of risk with
respect to implant stability26 and infection rates.17 27
Recently, a comprehensive surgical and rehabilitation
protocol (OGAAP-1) has been developed for procedures
involving osseointegrated implants which are currently
used in Australia and the Netherlands, with press-ﬁt
designs that encourage bone ingrowth.28 This protocol
emphasises an integrated approach for the management
of patients with lower limb amputations, and
revolves around two-stage osseointegration surgery with
a 4–6-week interval between stages. Preliminary results
have demonstrated signiﬁcant improvements in quality
of life and functional outcome measures,28 while maintaining very reasonable complication rates.29
Until very recently, the vast majority of osseointegration
procedures worldwide have been performed in two
stages. From the time of the initial surgery, these procedures require up to 12–18 months for the completion of
reconstruction and rehabilitation with screw-ﬁxation
implants, and at least 4–5 months even under the accelerated OGAAP-1 protocol.28 Since April 2014, however, a
single-stage osseointegration procedure has been routinely performed by the Osseointegration Group of
Australia (OGA) under the Osseointegration Group of
Australia Accelerated Protocol-2 (OGAAP-2). This protocol reduces the overall time required for the deﬁnitive
osseointegrated reconstruction and rehabilitation of
lower limb amputees to ∼3–6 weeks, which is substantially
shorter compared with any currently available two-stage
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procedure. This study aims to assess the safety and efﬁcacy of the single-stage OGAAP-2 procedure in a sufﬁciently large group of patients. The main hypothesis is
that the single-stage OGAAP-2 procedure will result in
more rapid progression to unrestricted full weightbearing with an osseointegrated reconstruction, within
an even shorter time frame compared with the two-stage
OGAAP-1 procedure, without an increased risk of associated adverse events.
Study objectives
The overall objective of this study is to assess the safety
and efﬁcacy of the single-stage OGAAP-2 procedure for
the osseointegrated reconstruction of lower limb amputations, and compare the beneﬁts and harms with
the outcomes obtained using the OGAAP-1 procedure
within 2 years of follow-up. Speciﬁcally, this involves:
1. Assessing the objective functional outcomes after
osseointegrated reconstruction of amputated limbs
using the single-stage OGAAP-2 procedure, with the
6 Minute Walk Test (6MWT), Timed Up and Go
(TUG) and K-levels, compared with preoperative
data and also data obtained using the previously
employed two-stage OGAAP-1 procedure.
2. Assessing the subjective patient-reported qualityof-life outcomes after osseointegrated reconstruction
of amputated limbs using the single-stage OGAAP-2
procedure, with the Questionnaire for persons with a
Trans-Femoral Amputation (Q-TFA) and the Short
Form Health Survey 36 (SF-36), compared with preoperative data and also data obtained using the previously employed two-stage OGAAP-1 procedure.
3. Examining the prevalence of adverse events after
osseointegrated reconstruction of amputated limbs
using the single-stage OGAAP-2 procedure, including
infection, revision surgery, fractures and implant failures, compared with data obtained using the previously employed two-stage OGAAP-1 procedure.
METHODS AND ANALYSIS
Overview of study design
The current prospective cohort study is designed to
assess the safety and efﬁcacy of the single-stage
OGAAP-2 procedure for the osseointegrated reconstruction of lower limb amputations within 2 years of
follow-up. The OGAAP-2 procedure is a comprehensive
programme for the management of patients with lower
limb amputation using single-stage osseointegration
surgery (ﬁgure 1). This procedure is exclusively performed by the OGA in Australia, and has been routinely
performed on eligible patients since March 2014.
Patients are evaluated by validated outcome measures
preoperatively and postoperatively. Preliminary data have
been obtained from an initial pilot study with 10
patients, which have been used to provide the sample
size estimate for the current study. The outcomes of this
study will be compared with those obtained using the

previously employed OGAAP-1 procedure at the same
follow-up time points.
Patient selection
Eligibility criteria
The inclusion criteria are age over 18 years, unilateral
transfemoral amputation and experiencing socketrelated problems or difﬁculties in using socket prostheses (including patients who are ambulatory with
assistive devices or non-ambulatory with short stumps
and non-reconstructable limb pathology). The exclusion
criteria are smoking, psychological instability, pregnancy,
limb exposure to radiation, ongoing chemotherapy,
immunosuppression, diabetes, peripheral vascular
disease and non-compliance during preoperative screening and evaluation.
Patient screening and recruitment
Prospective patients are referred by rehabilitation physicians, specialists, general practitioners (GPs) or prosthetists, or arise from direct enquiries. All prospective
patients are asked to complete a secure online enquiry
form found on the OGA website. If the patient has consented to communication, team contact occurs in the
form of a phone call to conﬁrm the patient’s medical
and social demographic history, prosthetic history,
general expectations and compliance, as well as to
discuss the exclusion criteria. Pain and psychological
questionnaires are then provided to the patient, and
used as tools for assessing the patient’s psychological
well-being and identifying any chronic pain issues.
Patients who satisfy the inclusion criteria are invited to
attend a specialised osseointegration clinic, during
which preoperative clinical, radiological and psychological examinations are performed, and baseline values
of outcome measures are recorded. The clinic also gives
an opportunity for prospective patients to receive
specialist team counselling, as well as to engage in
peer-to-peer interaction regarding the surgical procedure and recovery. After an individual consultation with
the specialist team, suitable patients are enrolled for
osseointegration surgery using the OGAAP-2 procedure,
and informed consent for data collection is obtained.
The ﬁrst deﬁnitive patient undergoing osseointegrated
reconstruction using the OGAAP-2 procedure was
enrolled on 9 April 2014. Enrolment is ongoing at the
time of publication and is expected to be complete by
December 2016.
Study intervention
Preoperative management
Surgical planning is conducted by using the patient’s
radiographs, CT scans and dual-energy X-ray absorptiometry (DXA) scans to determine the anatomy of the
skeletal residuum, as well as to allow patient-speciﬁc
selection of the implant type and size, and external prosthetic components. A preoperative physical training programme is recommended for all patients. This consists
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Figure 1 Overview of the single-stage Osseointegration Group of Australia Accelerated Protocol-2 clinical programme and
outcomes evaluation for the osseointegrated reconstruction of lower limb amputations.

of muscle strengthening and visualisation, and core
strengthening exercises (including abdominals and
upper body) for wheelchair-bound patients, and pregait
training aimed at increasing the range of movement
(with particular emphasis on the residuum hip ﬂexors
and adductors) for prosthetic users.
Osseointegration surgery
The surgical procedure involves permanent insertion of
the Osseointegrated Prosthetic Limb (OPL; Permedica s.
p.a; Milan, Italy) (ﬁgure 2). This osseointegration
implant system is speciﬁcally designed for press-ﬁt ﬁxation and consists of two components. The intramedullary stem component has proximal splines to facilitate
initial rotational stability, and a distal ﬂare to provide
initial axial stability. It also has a macroporous surface
structure resembling cancellous bone to facilitate bone
penetration. These design features provide rigid initial
stability, as well as permanent implant anchorage as a
result of bone ingrowth. The dual-cone adaptor component connects the intramedullary stem to the external
prosthesis and has a highly polished surface coated with
4

titanium-niobium dioxide to minimise soft tissue friction
and adhesions. The proximal aspect of the dual-cone
adaptor that connects to the intramedullary stem is provided with a safety pin, which fails under excessive torsional forces to prevent periprosthetic fracture or
implant breakage.
The procedure is performed in a single stage under
the OGAAP-2 protocol (ﬁgure 3). Prophylactic intravenous antibiotics using 2 g of cephazolin is administered
prior to the procedure, in accordance with standard
arthroplasty antibiotic prophylaxis protocols.30 The ﬁrst
part of the operation involves soft tissue preparation and
implantation of the intramedullary stem, which comprises a major portion of the surgery. This includes guillotine amputation of the stump without shortening of
the bony residuum, and reorganisation of the residual
muscle groups around the bone end using absorbable
purse string sutures. Haemostasis is achieved, and neuromas are identiﬁed and terminalised by shortening
the nerve endings and embedding them into the surrounding fatty tissue to avoid adhesions or tethering to
muscles. Additional soft tissue optimisation is then
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using speciﬁc rasps to match the distal ﬂange of the
implant. The intramedullary stem is then inserted into
the medullary canal of the residual femur by impacting
with a mallet to achieve a mechanically stable press-ﬁt
ﬁxation.
The second part of the operation involves attachment
of the transcutaneous dual-cone adaptor to the intramedullary stem. The appropriate size is selected by inserting the adaptor sizing guide through the skin opening.
The selected dual-cone adaptor is placed into the Morse
taper sleeve on the distal end of the intramedullary stem
and locked by impaction, then further secured with an
internal locking screw. The distal taper sleeve, bushing
and distal abutment screw are then attached to the distal
aspect of the dual-cone adaptor. The bushing contains a
two-pin external fail-safe mechanism, which limits the
risk of periprosthetic fracture. Once completed, local
anaesthetic is inﬁltrated proximal to the terminalised
nerves, as well as surrounding the stoma and incision
site.

Figure 2 The Osseointegrated Prosthetic Limb implant
system (Permedica s.p.a; Milan, Italy) used for the
osseointegrated reconstruction of trans-femoral amputations
under the Osseointegration Group of Australia Accelerated
Protocol-2 procedure. The implant consists of an
intramedullary stem component and a dual-cone adaptor
component.

performed with refashioning of the stump and excision
of excess subcutaneous fat to achieve a minimised soft
tissue envelope. The ﬁnal stage of soft tissue preparation
involves identifying the area of soft tissue opposing the
distal end of the bony residuum, and removing the fat
beneath a circular portion of skin in this area. The
dermis is then sutured around the periosteum, and the
wound is closed using metal staples with minimal
internal sutures. Under ﬂuoroscopy, a k-wire is inserted
through the de-fatted skin at the tip of the bony
residuum, followed by application of a circular skin
corer to create a percutaneous opening.
After haemostasis is achieved, the medullary canal is
prepared under ﬂuoroscopic guidance using sequential
ﬂexible reamers followed by implant-speciﬁc broaches.
Broaching is undertaken to the same size as the planned
implant size. However, in the presence of osteoporosis as
indicated by examination of the DXA scan, broaching is
undertaken to one size under that of the planned
implant size. The distal portion of the femur is prepared

Postoperative management
Pain management involves the administration of intravenous and epidural pain medications for the ﬁrst 3 days
following surgery, and oral analgesics thereafter. Wound
care involves daily dressing changes with dry ribbon
gauze and application of antiseptic solution for 10 days
postoperation. Patients are then advised to wash the
implant–skin interface two times per day with warm tap
water and soap, and to pat dry the skin opening with disposable paper towels. Patients are generally discharged
5–7 days after surgery. Staples are typically removed after
3–4 weeks.
Rehabilitation
Postoperative rehabilitation proceeds in three phases.
Phase I is initiated 3 days after surgery and consists of
the patient applying a static axial load of 20 kg for
20 min two times per day. The load is increased by 5 kg/day
until either 50 kg or 50% of the patient’s body weight is
reached. Phase II is initiated when the patient has
reached the recommended axial loading level. The
patient is ﬁtted with a rehabilitation prosthesis, which
includes a light leg with a stable locked knee. The
patient continues to perform core strengthening and
balance exercises, and gait exercises aided by parallel
bars. Phase III is initiated when the patient is safely
mobilising using the rehabilitation prosthesis. The
patient is then ﬁtted with the deﬁnitive prosthesis and
proceeds to daily weight-bearing. Postoperative rehabilitation should be concluded within 3–6 weeks following
osseointegration surgery.
Ongoing physiotherapy
After rehabilitation, the patient performs daily weightbearing using the deﬁnitive prosthesis, ﬁrst on two
crutches for 6 weeks, then on a single crutch in the
opposite hand for another 6 weeks and unaided
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Figure 3 Steps involved in
single-stage osseointegration
surgery under the
Osseointegration Group of
Australia Accelerated Protocol-2.
(A) Identification and
terminalisation of neuromas
during soft tissue preparation. (B)
Completed guillotine amputation
of the stump. (C) Reaming of the
medullary canal and preparation
of the distal femur to
accommodate the flange of the
intramedullary stem component of
the osseointegration implant. (D)
Insertion of the intramedullary
stem by impacting with a mallet.
(E) Creation of the stoma site and
insertion of the dual-cone adaptor
component of the
osseointegration implant. (F)
Stoma site postoperation,
showing the inserted dual-cone
adaptor and remaining parts of
the abutment.

thereafter. Meanwhile, further gait training is recommended that focuses on fall prevention and management, balance, walking and ascending and descending
slopes.
Study outcomes and follow-up
Study outcomes
The outcome measures of this study include: (1) objective functional outcomes measured using the 6MWT,
TUG and K-levels, (2) subjective patient-reported
quality-of-life outcomes measured using the Q-TFA and
SF-36 and (3) prevalence of adverse events including
infection, revision surgery, fractures and implant failures
after osseointegrated reconstruction of amputated limbs
using the single-stage OGAAP-2 procedure. A description of each of these validated outcome measures is provided below. In addition, perioperative parameters
including total surgical time (hours), intraoperative
bleeding (signiﬁcant (>300 cc) or not signiﬁcant), postoperative pain (numerical rating scale), total time in
hospital (days), time to deﬁnitive prosthetic ﬁtting
(days) and time to full weight-bearing (days) will be
recorded and compared with results obtained using the
previously employed OGAAP-1 procedure.
The 6MWT involves documenting, in metres, the
maximum distance covered by the patient in 6 min by
continuously walking along a 25 m long level enclosed
corridor.31 The TUG involves documenting the time, in
6

seconds, required for the patient to rise from a standard
armchair, walk to a line on the ﬂoor 3 m away, turn,
walk back to the chair and sit down again.32 K-levels are
deﬁned by the US Medicare system to categorise the
ability of lower limb amputees to ambulate and navigate
the environment, and uses a ﬁve-level functional classiﬁcation system (K0–K4, where K0 is deﬁned as inability to
ambulate and a prosthesis does not enhance quality of
life or mobility, and K4 is deﬁned as ability for prosthetic
ambulation that exceeds basic ambulation skills as exempliﬁed by a child, active adult or athlete).33 The results
of these functional outcome measures obtained after
osseointegrated reconstruction using the OGAAP-2 procedure will be compared with preoperative baseline
values, as well as with the results obtained using the previously employed OGAAP-1 procedure at the same
follow-up time points.
The Q-TFA is a self-report measure developed for
transfemoral amputees using a socket or osseointegrated
prosthesis to reﬂect prosthetic use, prosthetic mobility,
problems and global health, each in a separate score
(0–100).34 The SF-36 is a short-form health survey
designed for use in clinical practice and research, and
includes one multi item scale that assesses the eight
health concepts of physical functioning, social functioning, role limitations due to physical problems, bodily
pain, general mental health, role limitations due to emotional
problems,
vitality and
general
health
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perceptions.35 The results of these quality-of-life
outcome measures obtained after osseointegrated reconstruction using the OGAAP-2 procedure will be compared with preoperative baseline values, as well as with
the results obtained using the previously employed
OGAAP-1 procedure at the same follow-up time points.
The monitoring and recording of adverse events
involves identifying infections related to the osseointegrated implant on the basis of clinical and radiographic
ﬁndings, and grading them into ﬁve levels of severity: 0,
no infection; 1, low-grade soft tissue infection; 2, highgrade soft tissue infection; 3, deep bone infection or 4,
septic implant failure.29 Management of infections is
recorded as (A) oral antibiotics, (B) parenteral antibiotics,
or (C) surgical debridement and/or explantation.29 Other
adverse events are recorded and categorised into: stoma
hypergranulation, redundant soft tissue, proximal femoral
fracture, inadequate osseointegration with replacement of
implant, breakage of intramedullary component and
breakage of dual-cone component safety pin.29 The prevalence of adverse events after osseointegrated reconstruction using the OGAAP-2 procedure will be compared with
the results obtained using the previously employed
OGAAP-1 procedure at the same follow-up time points.
Study follow-up
All patients are followed for a minimum period of
2 years, with routine clinical monitoring conducted and
outcomes assessed at set intervals of 6 weeks, 3, 6 and
12 months after surgery and annually thereafter.
Radiographic outcomes are assessed at all follow-up intervals scheduled. 6MWT, TUG, Q-TFA and SF-36 outcomes
are assessed at 6 and 12 months, and annually thereafter.
DXA scans are performed at the 12-month follow-up, and
annually thereafter. All adverse events are managed when
identiﬁed as appropriate for the clinical conditions
encountered, and recorded at the time of occurrence.
Mechanisms of reporting adverse events include entries
in the patient’s diary booklet, reports from the patient’s
GP and any contact made directly to the clinical team.
The minimum follow-up period of 2 years is chosen as
our previous experience indicates that peak gains in
function and quality of life as a result of osseointegrated
reconstruction of amputated limbs are obtained within
12 months postoperation,28 and changes in related outcomes can be expected to plateau thereafter. Our previous experience also shows that 2 years of follow-up will
provide sufﬁcient time for the monitoring of any major
adverse events (such as infection) following surgery.29
Given the short time period required for deﬁnitive
osseointegrated reconstruction and rehabilitation under
the OGAAP-2 procedure, the most signiﬁcant changes
in measures of beneﬁts and harms are expected to be
observed within 6 months of follow-up.
Protecting against sources of bias
Owing to the nature of this study with one treatment
group
( patients
undergoing
single-stage

osseointegration surgery under the OGAAP-2) and no
simultaneous control group ( previously obtained data
from patients undergoing osseointegration surgery
under the OGAAP-1 will be used for comparison at the
same follow-up time points), the assessors of outcome
measures cannot be blinded. However, bias will be
unlikely for the functional and quality-of-life outcome
measures since these do not require the assessor’s subjective judgement. The results of functional outcome
measures (6MWT, TUG, K-levels) depend completely on
the patients’ physical performance, while the results of
quality-of-life outcome measures (Q-TFA, SF-36) are
derived completely from surveys of patient responses. To
avoid bias, the assessors collecting these results will not
be involved in the data analysis aspect of the study.
For the reporting of adverse events, patients are
advised to see their GP for suspected infection, and
cases of infection are typically managed by the GP
unless surgical intervention is required. The GPs are not
part of the core clinical and research team conducting
this study, and will therefore provide an unbiased diagnosis of any infection cases related to osseointegration
surgery. Information on cases of infection is relayed
back to the OGA team, and an infection grading is
assigned only after the case has been resolved. The level
of severity of the infection (0–4) is determined by a
group of surgeons and infection specialists to minimise
bias, while the method of management (A–C) is
assigned depending on the type of intervention and
does not require assessor judgement. Adverse events
other than infection are reported as the number of
cases occurring and are not subjected to bias.
Bias relating to surgeon expertise and protocol adherence is eliminated since all operations will be performed
by a single surgeon, who is the developer of the
OGAAP-2 protocol and initiator of this study.

Statistical plan and data analysis
Sample size estimate
Owing to the absence of previous literature on osseointegrated reconstruction using the OGAAP-2 procedure,
data from an initial pilot study with 10 patients have
been used to provide the most accurate sample size estimate possible. An a priori sample size calculation for
analysis of variance (ANOVA) has been performed to
determine the number of cases required to demonstrate
a statistically signiﬁcant ( p=0.05) difference between
preoperative and postoperative data for the functional
and quality-of-life outcome measures. The sample size
was calculated using the difference between the means
for four of the main validated outcome measures
(6MWT, TUG, Q-TFA and SF-36) based on the pilot
study data (table 1), assuming that α=0.5 and β=0.10
with a power of 0.90 (1−β). Based on these parameters,
the sample size calculations indicate that a minimum of
84 participants is necessary to provide a statistical power
of 90%. To account for dropouts related to death and
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Table 1 Sample size calculations comparing preoperative and postoperative pilot study data for the functional and
quality-of-life outcome measures, obtained for osseointegrated reconstruction under the Osseointegration Group of Australia
Accelerated Protocol-2 procedure
Pilot study outcome measures

Preoperative mean

Postoperative mean

SD

Estimated N

6MWT
TUG
Q-TFA (global score)
SF-36 (physical component score)

165
10.5
45.0
39.3

392
6.2
71.3
46.4

178
8.6
21.6
12.4

13
84
15
64

loss to follow-up (conservative estimate of 25%), a total
of 105 patients will be recruited for the current study.
Data analysis
Continuous outcome variables will be summarised by
calculating the mean and SE, and a KolmorogovSmirnov test will be used to determine the normality of
the data. Categorical outcome variables will be presented as frequencies and percentages. ANOVA will be
used to determine differences between preoperative and
postoperative values for each continuous outcome
measure. Fisher’s exact test will be used to examine the
signiﬁcance of the contingency of preoperative and postoperative K-levels. The Bonferroni corrections will be
performed to adjust for multiple comparisons. Multiple
two-way contingency tables will be created, and a twotailed Pearson χ² test with Yates corrections will be used
for comparisons as indicated. All statistical analyses will
be performed using Systat SPSS V.22.0 (IBM Corp.,
Armonk, New York, USA), where p<0.05 will be considered signiﬁcant for all comparisons.
DISSEMINATION
Ethical considerations
All patients included in this study will sign a consent
form that provides sufﬁcient information about the
study for patients to make an informed decision about
their participation. All patient data and personal information will be deidentiﬁed and maintained on a
password-enabled secure laptop computer.
Dissemination
Outcomes of the current study will be disseminated by
publications in peer-reviewed academic journals and presentations at relevant clinical and orthopaedic conferences. To minimise delay, the preparation of study
ﬁndings for dissemination will start as soon as data collection for the 2-year follow-up is complete for all
enrolled patients. A manuscript containing the major
ﬁndings of this study will be submitted for publication
regardless of the presence or absence of signiﬁcant
outcomes.
DISCUSSION
The ﬁndings of this study will make an important contribution to the small body of literature that is currently
8

available regarding the reconstruction and rehabilitation
of lower limb amputees using osseointegrated prostheses. The single-stage OGAAP-2 procedure enables the
patient to achieve rapid progression to deﬁnitive
osseointegrated reconstruction and full weight-bearing
after surgery, within a substantially shorter period of
time compared with any other currently available twostage procedure. By allowing single-stage surgery, the
new implant design used under the OGAAP-2 procedure
eliminates the minimum 6-week delay between surgical
stages that is required for two-stage procedures, and also
facilitates an accelerated postoperative rehabilitation programme that results in fast progression to unrestricted
and unassisted full weight-bearing. The OGAAP-2 procedure therefore dramatically reduces the overall treatment time to 3–6 weeks, which is comparable to that of
uncemented total hip arthroplasty procedures.36
The concept of osseointegrated reconstruction originated in the dental implant ﬁeld. Osseointegrated
dental implants were introduced in the 1960s and were
initially performed in two stages, where a 3–6-month
interval between stages allowed uneventful wound
healing prior to further intervention.37 Nevertheless, the
immediate loading of dental implants is now routinely
permitted, with multiple studies demonstrating the feasibility and predictability of the single-stage approach.38–40
A major research question answered by the current
study is whether the same concept of single-stage operation for dental implants can be applied to the osseointegrated reconstruction of amputated lower limbs.
If this study demonstrates that the single-stage
OGAAP-2 procedure leads to signiﬁcant improvements
in postoperative functional and quality-of-life outcomes
compared with preoperative levels without an increased
prevalence of adverse events, it will potentially reverse
the concept that a two-stage procedure is necessary to
achieve the safe and effective osseointegrated reconstruction of amputated limbs. This may have a substantial impact in shaping a new standard of treatment for
patients with lower limb amputations, which allows for
rapid recovery and the earliest possible return to daily
activities.
A limitation of this study is that direct comparisons
cannot be made with the outcomes of using socket prostheses, as the cohort of patients who are considered for
osseointegration surgery are either experiencing problems
with their socket prosthesis or are wheelchair-bound.
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Nevertheless, the current study compares preoperative
and postoperative values of functional and quality-of-life
outcome measures in patients undergoing osseointegrated
reconstruction under the OGAAP-2 procedure, which
gives an indication of the beneﬁts of osseointegrated prostheses as a solution for patients who have previously been
excluded from other types of prosthetic reconstruction.
Another limitation is the relatively short follow-up period
of 2 years. Although this time frame is considered sufﬁcient for assessing the important beneﬁts and harms of
the OGAAP-2 procedure, it does preclude the examination of long-term outcomes and the long-term risk of
adverse events. Larger prospective studies with longer
follow-up times will be necessary to fully evaluate the longterm safety and efﬁcacy of osseointegrated reconstruction
of lower limb amputations under the OGAAP-2 procedure.
The OGA team will continue to collect routine clinical
data from the patients of this study after the 2-year
follow-up, such that long-term retrospective analyses can
be performed at a later date.
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